TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37308969
Drug: Active PEMF
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PEMF treatment and eccentric exercise
Study: 37308969
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment and eccentric exercise
Study: 37308971
Drug: Xentuzumab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xentuzumab (1000 mg weekly intravenous infusion) with everolimus (10 mg/day orally) and exemestane (25 mg/day orally)
Study: 37308971
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with everolimus (10 mg/day orally) and exemestane (25 mg/day orally)
Study: 37309006
Drug: Compassion-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion-focused therapy (CFT) for 12 weeks
Study: 37309193
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg (DW1903) daily for 2 weeks
Study: 37309193
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg (DW1903R1) daily for 2 weeks
Study: 37309696
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency (ID) defined as serum ferritin < 100 μg/L or ferritin 100-299 μg/L with transferrin saturation < 20%.
Study: 37310391
Drug: BNT162b2 primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on anti-CD20
Study: 37310391
Drug: BNT162b2 primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on fingolimod
Study: 37310391
Drug: BNT162b2 primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 primary and booster vaccination (3 to 4 injections) in MS patients on other treatments
Study: 37310391
Drug: BNT162b2 primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 primary and booster vaccination in MS patients on other treatments
Study: 37310781
Drug: Digital training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital training (DT) course with weekly individualized coaching
Study: 37310877
Drug: Increased adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Increased adalimumab dose intervals
Study: 37310877
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing interval
Study: 37311468
Drug: Luspatercept (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luspatercept (1.0 mg/kg body weight subcutaneously every 3 weeks, titrated up to 1.75 mg/kg)
Study: 37311694
Drug: Polyethylene glycol-coated
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-coated patch
Study: 37311722
Drug: Danuglipron (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danuglipron (200 mg BID)
Study: 37311722
Drug: Danuglipron (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danuglipron (low [5-mg] or high [10-mg] starting dose, escalating to 80, 120 or 200 mg BID)
Study: 37312053
Drug: HYDRA proton-
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYDRA proton- and photon radiotherapy (40 Gy elective dose, 55 Gy simultaneous integrated boost, 59 Gy focal boost)
Study: 37312054
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of anti-PD-1 immunotherapy with avelumab
Study: 37312086
Drug: non-standard targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-standard targeted therapy based on potentially actionable molecular alterations or biomarkers
Study: 37312165
Drug: 2 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of neoadjuvant CAPOX (oxaliplatin 130 mg/m2)
Study: 37312165
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of neoadjuvant CAPOX (oxaliplatin 130 mg/m2)
Study: 37312233
Drug: Mepolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (300 mg subcutaneously every 4 weeks)
Study: 37313403
Drug: Toripalimab plus
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab plus chemotherapy (TC)
Study: 37313403
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (PC)
Study: 37314165
Drug: Idarucizumab (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (specific dabigatran reversal agent)
Study: 37314165
Drug: Andexanet alfa
Normalized name: andexanet alfa
DrugBank: Andexanet alfa (DB14562)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Andexanet alfa (for Xa inhibitors apixaban and rivaroxaban)
Study: 37314244
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g bolus before hospital admission, followed by 1 g infusion over 8 hours)
Study: 37314501
Drug: Neratinib 160
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 160 mg daily with trametinib 1 mg, 5 days on and 2 days off
Study: 37314501
Drug: Neratinib 160
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 160 mg daily with trametinib 1 mg daily (DL1)
Study: 37315268
Drug: Daratumumab, low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab, low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd)
Study: 37315268
Drug: Carfilzomib, lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide, or lenalidomide, dexamethasone, and cyclophosphamide (MyeXI treatment)
Study: 37315558
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular GRAd-COV2 administration
Study: 37315558
Drug: Second administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second administration of GRAd-COV2
Study: 37315558
Drug: Two vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two vaccine injections
Study: 37315579
Drug: CP-506 with
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CP-506 with single dose irradiation
Study: 37315590
Drug: Vortioxetine (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (initiated at 5 mg/day, up-titrated to 10 mg/day at day 8, flexible dosing thereafter [5-20 mg/day])
Study: 37315924
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention of DHA-rich fish oil (1.1 g/d DHA and 0.4 g/d EPA) and cocoa flavanols (500 mg/d flavan-3-ols)
Study: 37316311
Drug: Exenatide as
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide as an adjunct to nicotine patches
Study: 37316789
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of General Anesthesia and Regional Anesthesia
Study: 37316847
Drug: Dapagliflozin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin therapy
Study: 37317022
Drug: guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 200 mg SC every 4 weeks through Week 36
Study: 37317022
Drug: guselkumab 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 1200 mg IV for 12 weeks, then switched to guselkumab 200 mg SC every 4 weeks from Weeks 12 through 36
Study: 37317022
Drug: placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 12 weeks, then re-randomized to guselkumab 200 mg SC every 4 weeks or guselkumab 100 mg SC at specified weeks
Study: 37317993
Drug: Buparlisib (BKM120)
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (BKM120) monotherapy
Study: 37318085
Drug: Avatrombopag (AVA)
Normalized name: avatrombopag
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avatrombopag (AVA) at a starting dose of 20 mg/d, titrated to a maximum of 60 mg/d
Study: 37318116
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)
Study: 37318116
Drug: ICS/LABA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS/LABA + long-acting muscarinic antagonist (LAMA)
Study: 37318116
Drug: LAMA monotherapy
Normalized name: Lama palagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMA monotherapy
Study: 37318116
Drug: ICS-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS-containing therapy
Study: 37318349
Drug: Talazoparib 1
Normalized name: talazoparib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib 1 mg once daily for 24 weeks
Study: 37318379
Drug: Tucatinib in
Normalized name: Product containing tucatinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucatinib in combination with Trastuzumab
Study: 37318469
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine infiltration along the nephrostomy tract (20 mL)
Study: 37318707
Drug: LipiFlow treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipiFlow treatment prior to cataract surgery
Study: 37318707
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LipiFlow treatment prior to surgery)
Study: 37318707
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group after crossover (received LipiFlow treatment)
Study: 37318750
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg Q2W
Study: 37318808
Drug: Escitalopram, Sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, Sertraline, or Venlafaxine extended-release (1:1:1 randomization)
Study: 37319244
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg modified-release prednisone
Study: 37319432
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg IV every 3 weeks for up to 8 cycles after ASCT.
Study: 37319438
Drug: Oral Octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Octreotide Capsules (OOC)
Study: 37319438
Drug: Transitioning from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transitioning from injectable somatostatin receptor ligands (iSRLs) to Oral Octreotide Capsules (OOC)
Study: 37319437
Drug: Abatacept (IV)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept (IV) with a target trough of 10 μg/mL and higher Ctrough_1 (≥39 μg/mL)
Study: 37319437
Drug: Abatacept (IV)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept (IV) with Ctrough_1 <39 μg/mL
Study: 37321663
Drug: Intratumoral T4
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratumoral T4 immunotherapy (CAR-T cells)
Study: 37322121
Drug: Therapies matched
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies matched to genomic alterations in 27 substudies
Study: 37322274
Drug: IV-golimumab 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-golimumab 2 mg/kg at week 0, week 4, then every 8 weeks
Study: 37322367
Drug: Sugemalimab plus
Normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab plus chemotherapy (1,200 mg every 3 weeks)
Study: 37322482
Drug: Latozinemab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latozinemab (single infusion)
Study: 37322482
Drug: S15JG (anti-sortilin
Approvals — FDA: no, EMA: no, PMDA: no
Description: S15JG (anti-sortilin antibody)
Study: 37322511
Drug: Bipolar haemostatic
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bipolar haemostatic forceps (HemoStat/Pentax®) as experimental therapy (ET)
Study: 37322511
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ST) using haemoclip + / - epinephrine injection
Study: 37322538
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (3 g of probiotic preparation including eight bacterial strains)
Study: 37322538
Drug: Prebiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic supplementation (5 g of oat bran)
Study: 37323059
Drug: GSK2831781 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2831781 450 mg intravenously (IV)
Study: 37323099
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg orally once a week)
Study: 37324622
Drug: MEDI-app (smartphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-app (smartphone app with alarm for drug intake, visual confirmation of drug administration, medication intake history)
Study: 37324622
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (conventional treatment)
Study: 37325226
Drug: Enhanced External
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced External Counter Pulsation (EECP) therapy
Study: 37325545
Drug: Amsterdam Instrumental
Normalized name: AE-aspergillus amsterdami
DrugBank: Eurotium amstelodami (DB15526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q)
Study: 37325545
Drug: Alzheimer's Disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
Study: 37325662
Drug: Control (23-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (23-valent pneumococcal polysaccharide vaccine and inactivated hepatitis A vaccine)
Study: 37325860
Drug: afamitresgene autoleucel
Normalized name: Afamitresgene autoleucel
DrugBank: Afamitresgene autoleucel (DB18592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: afamitresgene autoleucel (afami-cel) therapy after low-dose radiotherapy (LDRT) at 5.6 Gy/4 fractions to the liver
Study: 37325860
Drug: low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose radiotherapy (LDRT)
Study: 37325931
Drug: Triple-negative receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-negative receptor subtype
Study: 37326322
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (1.62% daily, adjusted to maintain testosterone levels between 350 and 750 ng/dL)
Study: 37326322
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (1.62% daily)
Study: 37326473
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of meropenem
Study: 37326473
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of meropenem
Study: 37326942
Drug: SHR2285 (25-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2285 (25-600 mg single ascending doses)
Study: 37326942
Drug: SHR2285 (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2285 (100-400 mg multiple ascending doses)
Study: 37327046
Drug: Self-reported number
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported number of doses
Study: 37327046
Drug: Self-reported brand
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported brand of the first dose
Study: 37327046
Drug: Self-reported brand
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported brand of the second dose
Study: 37327046
Drug: Self-reported brand
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported brand of the third dose
Study: 37327113
Drug: Romidepsin 10
Normalized name: romidepsin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romidepsin 10 mg/m2 IV on days 1, 8, and 15 plus lenalidomide 25 mg orally from days 1 to 21 of a 28-day cycle for up to 1 year
Study: 37327230
Drug: Humanoid robot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanoid robot Pepper used at home by children with cochlear implants and their families for 1 month.
Study: 37327369
Drug: Topical Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical Azithromycin
Study: 37327369
Drug: Oral Doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Doxycycline
Study: 37327461
Drug: Dato-DXd 6
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dato-DXd 6 mg/kg once every 3 weeks
Study: 37327527
Drug: Apixaban (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (therapeutic doses)
Study: 37327677
Drug: emtricitabine-tenofovir disoproxil
Normalized name: Emtricitabine-Tenofovir Disoproxil Fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: emtricitabine-tenofovir disoproxil fumarate (F/TDF) or emtricitabine-tenofovir alafenamide (F/TAF) given as a double dose once either 5 or 21 hours before ex vivo HIV-challenge.
Study: 37328392
Drug: Biolimus A9™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biolimus A9™ drug coated balloon (BA9-DCB)
Study: 37328736
Drug: Alirocumab (LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (LDL-C < 25 mg/dL)
Study: 37328736
Drug: Placebo (LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (LDL-C < 25 mg/dL)
Study: 37328736
Drug: Alirocumab (LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (LDL-C < 15 mg/dL)
Study: 37328736
Drug: Placebo (LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (LDL-C < 15 mg/dL)
Study: 37328751
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive behaviour therapy (CaCBT)
Study: 37328835
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose gemcitabine (Gem)
Study: 37328835
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose gemcitabine and nab-paclitaxel (GemNab)
Study: 37328855
Drug: Focused ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused ultrasound (FUS) at 220 kHz with systemically administered microbubbles, administered in three successive procedures at 2 week intervals.
Study: 37328859
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg)
Study: 37955825
Drug: Sotrovimab 500
Normalized name: sotrovimab 500 MG in 8 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrovimab 500 mg IV infusion
Study: 37328890
Drug: Sotrovimab 2000
Normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Sotrovimab 2000 mg IV infusion
Study: 37328890
Drug: Sotrovimab (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrovimab (dosing intervals to be defined)
Study: 37328931
Drug: semaglutide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 0.1 mg
Study: 37328931
Drug: semaglutide 0.2
Normalized name: SEMAGLUTIDE 0.25MG/0.375ML INJ PEN 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 0.2 mg
Study: 37328931
Drug: semaglutide 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 0.4 mg
Study: 37328931
Drug: semaglutide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide (all doses pooled)
Study: 37329361
Drug: Three preoperative
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three preoperative intravitreal (IVI) aflibercept injections with a monthly interval; the third injection was given intra-operatively (Group A)
Study: 37329361
Drug: Single intra-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intra-operative injection and two post-operative injections with a monthly interval (Group B)
Study: 37329415
Drug: Bamlanivimab and
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab and etesevimab (BAM + ETE) - open-label weight-based dosing (WBD, n=94)
Study: 37329633
Drug: Chios Mastiha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chios Mastiha Essential Oil (CMEO) 200 mg daily for 3 months
Study: 37329891
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan 6.4 mg/kg intravenously every 3 weeks until disease progression, withdrawal, physician decision, or death
Study: 37329900
Drug: KAN-101 (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAN-101 (0.15 mg/kg, 0.3 mg/kg, 0.6 mg/kg)
Study: 37329900
Drug: KAN-101 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAN-101 (all doses)
Study: 37329979
Drug: 2x taVNS
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x taVNS (twice daily)
Study: 37329979
Drug: 1x taVNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x taVNS (once daily)
Study: 37330484
Drug: Bioclear matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioclear matrix with injection molding technique
Study: 37330928
Drug: Restrictive IV
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive IV fluid therapy
Study: 37330974
Drug: Lumbar drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar drain (5 mL per hour) started within 72 hours after aneurysmal subarachnoid hemorrhage
Study: 37330974
Drug: Lumbar drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar drain (5 mL per hour)